The Filing Desk

Arcutis Biotherapeutics

ARQT · Nasdaq · Health Care · Financials, fiscal 2018 to 2025

ARQT · Last close · November 13, 2026
$28.26
Value Arcutis Biotherapeutics yourself

Arcutis Biotherapeutics' revenue rose 91.3% to $376 million in fiscal 2025. Its operating margin was −3.2%, up from −65.3% a year earlier. Free cash flow was −$6 million. The diluted share count rose 5.2%.

ARCUTIS BIOTHERAPEUTICS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 25, 2026 · 0001787306-26-000018 Updated
Revenue
$376M
91.3%
Operating margin
−3.2%
62.1 pts
Net income
−$16M
 
Free cash flow
−$6M
 
Return on capital
−16.9%
 
Market cap
$3.9B
Nov 13 close
P/E
134.6x
On $0.21 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Arcutis Biotherapeutics does

Arcutis Biotherapeutics sells prescription treatments for skin diseases. It describes itself as a commercial-stage company, meaning its products are approved and on sale, and it says it has four approved products.

Its lead product is ZORYVE, a once-daily, steroid-free medicine based on roflumilast, which blocks an enzyme called PDE4. ZORYVE cream launched in the U.S. in August 2022 for plaque psoriasis and is now approved for patients as young as 6; Arcutis has asked the FDA to extend this to children down to age 2. ZORYVE foam is approved for seborrheic dermatitis, a scaly skin condition, in people 9 and older. ZORYVE cream also launched in Canada in 2023.

Arcutis makes money by selling these products, which depend on doctors prescribing them and on insurers paying for them. It also has other product candidates in development. It has a loan agreement with operating and financial conditions it must meet.

Its biggest risks, as it describes them

  • It has lost money since it began and could keep doing so.
  • Its business depends on the commercial success of ZORYVE and on new products getting approved.
  • Insurers and drug plans may not cover its products or may pay too little for them.
  • Its loan agreement has operating and financial conditions that limit its flexibility.
  • Clinical trials are slow, costly and uncertain.
From Arcutis Biotherapeutics's annual report on Form 10-K, filed February 25, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Arcutis Biotherapeutics lost money in fiscal 2025: a net loss of $16 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments387410272228221
Debt incl. finance leases72198202107109
Net debt (negative means net cash)−315−212−70−121−112
Net debt to EBITDA—————
Debt to equity0.2x0.9x2.3x0.7x0.6x
Interest coverage—−19.3x−8.1x−4.7x−1.0x
Current ratio12.1x11.6x7.1x4.2x3.2x
Quick ratio12.1x11.4x6.8x4.0x3.0x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Arcutis Biotherapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Arcutis Biotherapeutics says to expect

  • Full year 2026: net product salesThe Company raised net product sales guidance for the full year 2026 to $535 million–$545 million from $525 million–$540 million.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 4, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Arcutis Biotherapeutics shares on the open market, and 10 insiders sold $12.2 million, $9.6 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 16, 2026Masaru MatsudaSee RemarksSold plan3,674$25.00$91,850Form 4
Sep 15, 2026Howard G. WelgusDirectorSold plan4,730$24.18$114,371Form 4
Sep 8, 2026Masaru MatsudaSee RemarksSold plan9,989$25.03$250,025Form 4
Aug 27, 2026Terrie CurranDirectorSold38,200$25.03$956,146Form 4
Aug 20, 2026Terrie CurranDirectorSold1,072$26.04$27,915Form 4
Aug 19, 2026Patrick BurnettSee RemarksSold1,697$27.00$45,819Form 4
Aug 17, 2026Howard G. WelgusDirectorSold plan4,730$26.18$123,831Form 4
Aug 12, 2026Patrick BurnettSee RemarksSold6,700$26.08$174,736Form 4
Aug 11, 2026Patrick BurnettSee RemarksSold8,300$26.52$220,116Form 4
Aug 3, 2026Todd WatanabeSee Remarks, DirectorSold plan4,375$26.12$114,275Form 4
Aug 3, 2026Masaru MatsudaSee RemarksSold plan1,230$26.12$32,128Form 4
Aug 3, 2026Patrick BurnettSee RemarksSold plan955$26.12$24,945Form 4
The latest 12 of 50 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 94 of 94 of 9
Rule of 401,101.9%172.6%89.7%
Altman Z''−8.30−7.30−3.68
Accruals ratio−3.8%−8.1%−2.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassPass
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rosePassFailFail
Revenue rose relative to assetsPassPassPass
F-score4 of 94 of 94 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Arcutis Biotherapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Arcutis BiotherapeuticsFY2591.3%−3.2%−1.7%−16.9%—4
MannKindFY2522.2%11.1%3.9%—3.6x4Compare
ArdelyxFY2522.1%−10.1%−10.8%−36.1%—2Compare
InnovivaFY2514.7%39.8%47.6%17.9%—6Compare
CorMedixFY25617.0%48.2%55.4%—−0.9x—Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

8 years of figures

Fiscal yearFY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue——00460196376
Revenue growth—————1,517.1%229.7%91.3%
Gross profit———0355177339
Research and development18361151461821117677
Operating income−20−43−137−206−302−241−128−12
Net income−19−42−136−206−312−262−140−16
Diluted EPS (US$)−15.53−22.78−3.80−4.18−5.66−3.78−1.16−0.13
Diluted shares (millions)1236495569121127
Cash flow
Cash from operations−14−43−113−175−258−247−112−6
Capital expenditure00010001
Free cash flow−14−43−113−176−258−247−112−6
Dividends paid00000000
Share buybacks00000000
Acquisitions00000000
Stock-based compensation0182433394240
Balance sheet at fiscal year end
Cash and short-term investments39101284387410272228221
Debt incl. finance leases——072198202107109
Total assets—107298408449341349433
Total liabilities—628110240253191244
Shareholders' equity−24−6527129821089158190
Margins and ratios
Gross margin————79.5%91.6%90.3%90.2%
Operating margin————−8,183.0%−404.5%−65.3%−3.2%
Net margin————−8,449.8%−439.8%−71.2%−4.3%
Free cash flow margin————−7,000.8%−415.2%−57.1%−1.7%
Rule of 40 (growth + FCF margin)—————1,101.9%172.6%89.7%
Return on capital———————−16.9%
Return on equity——−132.0%−72.6%−122.8%−175.8%−113.8%−9.3%
Return on assets——−67.0%−58.4%−72.7%−66.3%−40.6%−4.1%
Net debt to EBITDA————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Arcutis Biotherapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Arcutis Biotherapeutics.